Press Releases

March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […] READ MORE

December 17, 2019 The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common complication of lupus causing inflammation of the kidneys that can result in end-stage kidney disease. Called BLISS-LN, this Phase 3 trial is the largest one […] READ MORE

November 26, 2019 – New York, NY – The Lupus Research Alliance (LRA) 2019 Breaking Through Gala gathered more than 600 members of the global lupus community last night to raise $3 million, all of which goes directly to lupus research. The theme, Breaking Through, celebrates the many research discoveries that LRA makes possible to […] READ MORE

NEW YORK, NY – November 11. The Lupus Research Alliance (LRA) congratulates AstraZeneca on new positive results from the Phase 3 TULIP-2 trial (Treatment of Uncontrolled Lupus via the Interferon Pathway) presented at the 2019 ACR/ARP Annual Meeting.  The data showed that the investigational biologic treatment anifrolumab significantly reduced disease activity for people with lupus. […] READ MORE

NEW YORK, Nov. 10, 2019 /PRNewswire/ — The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by Genentech at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting showing the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for the most severe […] READ MORE

Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […] READ MORE

NEW YORK, October 24 — The Lupus Research Alliance proudly announces two exceptional recipients of the 2019 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity:  Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD. The highly prestigious up-to-$1 million grant will allow each investigator to test promising approaches for potential new lupus treatments. Dr. Mackay […] READ MORE

NEW YORK, NY. October 16 — The Lupus Research Alliance (LRA) is pleased to announce that seasoned professional Penny Mitchell has joined the organization as Senior Director of Marketing and Communications. In her new role, Ms. Mitchell will oversee the organization’s strategic communications approach to leading lupus research worldwide and the value of participation by […] READ MORE

NEW YORK, NY. August 29 — The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. Over 15 studies […] READ MORE

New York, NY, July 18, 2019 — Renowned Dr. Daniel Wallace joined the Lupus Research Alliance (LRA) affiliate Lupus Therapeutics  Board of Directors.   This governing body, which includes lupus patients, family members and scientists,  provides strategic insight and financial oversight to help Lupus Therapeutics achieve its mission –accelerate new ways to diagnose and treat lupus. READ MORE

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and clinical research affiliate, Lupus Therapeutics, broadened a collaboration with Bristol-Myers Squibb (BMS) to study the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN) – kidney damage affecting about 50 percent of people with lupus. This expands the existing collaboration in systemic lupus erythematosus (SLE). […] READ MORE

NEW YORK, NY. June 19, 2019. The U.S. House of Representatives today passed the Fiscal Year 2020 Defense Appropriations Act, which allocates the Lupus Research Alliance advocate’s full request for $10 million — double the current budget — for the Lupus Research Program in the Department of Defense’s (DoD) Congressionally Directed Medical Research Program. The […] READ MORE